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Possible Etiologic Mechanisms in Chemical
Carcinogenesis
by Emmanuel Farber*
Some highlights in the development ofourknowledge about carcinogens as etiological agents forcancer
are reviewed briefly. Advances during the past 20 years relating to metabolic activation with the genesis
of reactive metabolites, molecular targets and their interactions with activated carcinogens, oncogenes
as molecular targets and the dependence on cell proliferation, all relating to the initiation process, are
reviewed. Critical to initiation is the new phenotype in the initiated cell, known only in one instance, the
rat liver, in which the characteristic change is one ofresistance to many xenobiotic influences. The need
for clonal expansion of initiated cells as essential for carcinogenic effects is discussed. Differential in-
hibition has been shown as a dominant mechanistic pattern in the liver. In other systems, the manner in
which clonal expansion is achieved is not evident. The need for studies of the processes involved in
carcinogenesis, as well as the agents, is emphasized, in view ofthe continuing validity ofthe cell concept
as the key to integrating the increasingly large volume of data from the molecular with the biological.
Introduction
The past 20 years have seen a remarkable change in
attitude on the part of the medical and scientific com-
munity and of the public concerning causal factors in
cancer development. The dominant theme in the 1940s,
often unstated, was that when someone developed can-
cer, it was somehow their fault or their family's fault.
Today, the fault lies in the environment. This radical
change in perception occurred in the 1960s, just about
the time of organization of the National Institute of
Environmental Health Sciences.
This change inperception occurred for many reasons,
both scientific and sociological. Two major factors were
the realizations that smoking was a major cause of can-
cer and other chronic diseases, as focused by the report
ofthe Surgeon General'sAdvisory Committee on Smok-
ing and Health (1964), and distinctive ethnic groups
living in one country, such asJapan, left their patterns
ofcancer and otherdiseaseincidencesbehindwhenthey
migrated to the United States, and their children be-
came more integrated into the new country. The chil-
dren acquired the disease patterns characteristic of
North America, not the country of origin of their par-
ents and grandparents.
This emphasis on environment brought into focus the
known majoretiologic agents for cancer: viruses, chem-
icals, and radiation (Table 1). So far, quantitatively,
chemicals, in the form of smoking and occupation, are
related to 35 to 40% or so of cancers in the Western
World. Whether the majority of the remaining 60 to
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Table 1. Etiological agents in cancer.
Agents that can be transcribed or translated
RNA viruses (retroviruses)
DNA viruses
Oncogenes
Agents that destroy or alter information in target cells
Chemicals
Combined initiators-promoters (most carcinogens)
Initiators
Promoters
Radiation
Other
Nongenotoxic carcinogens
Foreign inert material
Dietary deficiency of choline
75% of cancers are also related to chemicals in the en-
vironment is unknown, even though many scientists
have expressed their personal bias in favor ofthis like-
lihood.
Let us now look at mechanisms with emphasis on
chemicals. Itis nowclearthatinmostifnotall systems,
chemicals, to be carcinogens, have to have at least two
major effects in general. One is the ability to induce
special changes in a few target cells that are largely
irreversible. This initiation actioninvolvesusually 1 per
105 or 106 target cells (liver, skin?) (1,2). The second
effect is the ability to cause the expansion by cell pro-
liferation ofthe initiated cells, presumably as examples
ofclonalexpansion. Thispromotion actionusuallytakes
place automatically afterthe initiationwhenlarge doses
or multiple or continuous doses ofcarcinogen are used.
However, it can be brought about by the use of theE. FARBER
same carcinogen as for initiation, different carcinogens
(3,4), or promoting agents with little or no ability to
initiate. Forthe many tissues or organs that show little
or no cell proliferation at the time of exposure (liver,
pancreas, urinary system includingkidney and bladder,
salivaryglands, respiratoryepithelium, centralnervous
system, etc.), a third property is important: the ability
to induce cell proliferation, either as a direct primary
mitogenic effect orasecondaryregenerative effectafter
cytotoxic cell death (Table 2).
Initiation
Initiation has received much attention in the past 20
years. The advance in our knowledge has been very
significant, even though we still do not know the fine
details concerning mechanisms.
Metabolic Activation
The major advances occurred in the 1960s and early
1970s with the establishment ofthe need for metabolic
conversion of most carcinogenic xenobiotics to highly
reactive derivatives, most commonly electrophilic re-
actions orelectrophiles (5). Mostknowncarcinogens are
metabolized by cytochrome P-450 mixed function oxy-
genasesystems, localizedmainlyinthemicrosomes, but
also in the nuclei. Recent research has indicated the
presence of many cytochromes P-450, at least 10 or 12
and perhaps more. These cytochromes have different
chemical, biochemical, and biological properties, even
though there is considerable overlap between different
forms. This overlap, although making trouble for the
biochemist, is most appropriate when one views the
needforawide spectrumofenzyme activities tohandle,
physiologically, the equally wide spectrum ofxenobiot-
ics and endogenous possible substrates with which the
organism is confronted.
The mixed functionoxygenase cytochrome P450 sys-
tem is not the only one active in metabolizing potential
carcinogens (Table 3). Reduction with DT-diaphorase
(quinone reductase) (e.g., nitroflurans, nitroquinoline-
N-oxide, nitropolycyclics, etc.); reaction with glutathi-
one (e.g., 1,2-dibromoethane, 1,2-dichloroethane); hy-
drolysis with specific enzymes, such as intestinal bac-
terial P-glucuronidase (e.g., cycasin); and other en-
zymes and oxidation via the prostaglandin system or
Table 2. Minimum requirements for a chemical to be a
carcinogen.
Interact with tissue components, e.g., DNA
Directly
After metabolic activation
Induce cell proliferation
Directly
Via cell death
Promote-create an environment in the tissue for selective
growth of initiated cells
Table 3. Metabolic generation of carcinogenic metabolites from
xenobiotics.
Microsomal cytochrome P-450 system (microsomes and nuclei)
Alternate pathways, e.g., aromatic amines
Sequential or linear, e.g., polycycic aromatic hydrocarbons
Cytosolic reductases (DT-diaphorase or quinone reductase)
e.g., nitroquinone, nitroquinolines, nitrofurans and
nitropolycyclics
Glutathione (with or without GSH-S-transferases)
e.g., 1,2-dibromoethane, 1,2-dichloroethane
Prostaglandin synthesis system or reactive oxygen species
e.g., polycyclic aromatic hydrocarbons
Selective enzymatic hydrolysis
e.g., ,B-glucosidase on cyeasin in intestine
via reactive oxygen species (e.g., polycyclic aromatic
hydrocarbons) are four additional known systems.
Inthe case ofthe dominant system, the mixed function
oxygenase system, there are some conceptual puzzles (6).
In respect to the metabolism of the polycyclic aromatic
hydrocarbons, the active derivative appears to be the
same for detoxification as well as for activation for car-
cinogenesis. Which pathway predominates appears to be
a function of the environment-diet and nutrition, other
xenobiotics, etc. This view is conceptually quite accept-
able. However, with aromatic amines, in which the gen-
esis of an active carcinogenic derivative is a very minor
pathway, the conceptual basis for this minor pathway
seems obscure. Does this pathway have some survival
value to an organism, or is it simply a necessary but
useless accompaniment ofthe major pathways for metab-
olism and detoxification, the ring hydroxylation?
An exciting development has been the preparation
and use of possible reactive derivatives by enzymatic
or chemical procedures. Highly reactive derivatives of
aromatic amines, polycyclic aromatic hydrocarbons
(e.g., 7,8-dihydrodiol, 9,10-epoxide of benzo[a]pyrene)
and other types of metabolites have been tested for
potency as carcinogens in both in vivo and in vitro sys-
tems with many interesting findings (7).
In addition, studies with various inhibitors or modi-
fiers of the metabolic activation systems have yielded
significant results concerning the possible enzymatic
mechanisms for activation (7). On the whole, these re-
sults have confirned in a clear-cut fashion the depen-
dence of many carcinogens for their carcinogenic effi-
cacy on metabolic activation and conversion to reactive
compounds. This phase of chemical carcinogenesis,
while by no means complete, is gratifying in showing
that the first step in chemical carcinogenesis is host
activityrelatingtometabolism. Thepossiblemodulation
of this first step by diet, hormones, drugs, and other
xenobiotics and the correlation of these observations
withthe ultimate cancerdevelopment is impressive and
offers models for the possible prevention of cancer in
humans ifthe nature ofthe etiologic agent is known but
somehow cannot be removed from the human environ-
ment.
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Molecular Targets
The molecular targets for the electrophilic reactions
are many-DNA, RNA, proteins, sulfhydryl groups,
polysaccharides, etc. Itiswidelybelievedthatthemajor
targetis DNA. Ashasbeenrepeatedlyshown, the DNA
targets for carcinogens may be the bases themselves,
the phosphate groups, or the three-dimensional struc-
ture of DNA (8,9). An impressive literature exists on
the manydetailsconcerningthespecificadductsformed,
their reactivity, and possible relevance to the ultimate
development of cancer and highly sensitive techniques
for their measurements. Adducts at sites ofH-bonding
(0-6-alkyl guanine, 0-4-alkyl thymine, etc.) have re-
ceived the primary attention recently because of their
obvious promutagenic nature. However, other lesions
such as N-7-alkylguanine and N-3-alkyl adenine are
known to consist of more than one form, as they show
different rates ofrepair. These lesions are repaired by
base removal, a lesion that seems equally dangerous if
DNA replication occurs before the normal base is in-
serted.
A potentially very important development is the as-
sessment of exposure (not risk) of humans to specific
carcinogens with the use of assays for derivatives of
DNA and protein adducts in blood, urine, and other
tissue components or fluids. This aspect of biochemical
epidemiology is discussed in detail by Curt Harris in
this issue.
Oncogenes as Molecular Targets
The recent resurgence of the oncogene concept, and
especially the identification of some oncogenes as re-
lated to the proliferative cell cycle (c-fos, c-myc, c-Ha-
ras, c-Ki-ras, c-myb, P53), other oncogenes as related
to knowngrowth factors and/orgrowth factorreceptors
such as platelet derived growth factor (PDGF) and ep-
idermal growth factor (EGF), and still other oncogenes
related to the systems for signal transduction from the
cell membrane have opened up many new areas in cell
biology. These offer the promise of new insights into
the biochemical and molecular basis for normal cell be-
havior. What roles they play, if any, in most carcino-
genic processes remains to be critically evaluated (10-
12). The induction ofspecific mutations in the c-Ha-ras
gene by N-methyl-N-nitrosourea and by dimethylben-
zathracene in the mammary gland of rats and skin of
mice and in benign or malignant neoplasms in these
tissuesandinthe same genein mouse andrathepatomas
(13-15), asreviewedbyMarshallAndersoninthisissue,
ispotentiallymostinteresting. Thescientific community
will await with great interest the results ofcritical con-
trol experiments that should aid in the decision as to
whether these mutations are passive accompaniments
of exposures to known mutagens such as many carcin-
ogens, or whether they become, on activation, inti-
mately involved mechanistically in the development of
cancer. How many other genes show mutations at the
same time? Why does c-Ha-ras seem to be the main or
only oncogene affected? Does it have a much greater
propensity for mutation ("hot spots")? Ifit is involved,
what mechanistic hypotheses forits possible function in
the carcinogenic process can be proposed? If it is in-
volved, in which of the several steps [at least 8 or 9
(16)] is it involved and how? Answers to some ofthese
critical questions would clarify to significant degrees at
leastsome aspectsofhowcancerdevelopswithchemical
carcinogens. Critical experiments in the mammary
gland, skin, and liver must include data on whether the
same mutations can be found when tissue exposed to
the carcinogen under initiating conditions is stimuated
to undergo nonneoplastic cell proliferation such as dur-
ing pregnancy in the mammary gland, nonpromoting
hyperplasia in the skin, and nonneoplastic hyperplasia
in the liver. True mutations would not likely be ofsuf-
ficient numbers to be detectable in the original target
tissue but might become detectable when the cells car-
rying them are amplified as in a papilloma or a nodule.
Dependence on Cell Proliferation
The major conceptual and technical advances in the
metabolism of carcinogens during the first step in ini-
tiation must now enter a new phase. How does one
relate these events to the biological cellular aspects of
cancer development? For example, we know that while
the activation of a carcinogen to a reactive derivative
and the interactions of these with cellular DNA and
other macromolecules are essential first steps, they are
insufficient to initiate carcinogenesis. Both in vitro and
in vivo, initiation does not occur unless followed by a
round ofcellproliferation (16,17). Although this is most
strikingly and clearly shownintheliver(18) andinvitro
(19), there are many indications that this may be a gen-
eral phenomenon for chemical carcinogenesis and for
other types ofcarcinogenesis (20). In the liver, a large
number of carcinogens are activated to reactive prod-
ucts and these interact with DNA and other cell com-
ponents. Yet most carcinogens are not carcinogenic for
the liver. However, ifcoupled with a round ofcell pro-
liferation, many if not all of these now initiate carcin-
ogenesis in the liver (21,22).
This dependence ofinitiation on cell proliferation has
made it possible to determine whether the short-lived
or long-lived adducts in DNA might be related to the
initiation of carcinogenesis in the liver. With diethyl-
nitrosamine and benzo[a]pyrene, ithas been shownthat
only the short-lived, i.e., adducts lasting no more than
72to96hr, aremostrelevanttotheinitiationofchemical
carcinogenesis in the liver (23).
Another important feature of initiation is the repair
oftherelevantbiochemicallesionorlesions, presumably
in DNA. This topic has blossomed in the past 20 years
and has established firmly that with ultraviolet light as
the carcinogen for the skin, DNA repair is a major de-
terminant in cancer development. The high incidence of
both squamous cell carcinoma and malignant melanoma
in patients with xeroderma pigmentosum is an experi-
ment of nature that has given us considerable insight
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into the possible role ofDNA alterations in carcinogen-
esis.
This experience with xeroderma pigmentosum em-
phasizes in a major way the probable role of altered
DNA in the first step in initiation of chemical carcino-
genesis. Although this is often formulated in terms of
mutations leading to base substitutions, the evidence
for this is so far not convincing. No abnormal protein,
with altered amino acid sequence, asindicative ofabase
substitution in the corresponding gene, has been found
during initiation, with the exception ofan altered c-Ha-
ras gene in a few patients with cancer of the urinary
bladder and inmammarygland intheratafterexposure
to N-methyl-N-nitrosourea (10). In the experimental
system, no evidence that the altered gene had any role
to play in the carcinogenic process was provided. The
immediate mutagenic effect ofa mutagen was ofcourse
anticipated. Future mechanistic experimental studies
may clarify this potentially excitingobservation, as dis-
cussed above.
Given the newer insights into the dynamism of the
mammalian genome, it is possible that carcinogenesis
might be related to translocations, transpositions, gene
amplifications, or other gene or DNA rearrangements
rather than to a change in the base sequence. One can
anticipate innovative overtures along these exciting
lines in future studies on chemical carcinogenesis.
The dependence of initiation of carcinogenesis on a
round ofcell proliferation may indicate aneed for DNA
replication in order to effect the change in gene expres-
sion related to the carcinogen-induced DNA alteration.
However, since the cell cycle has so many component
parts in addition to DNA replication, including the ac-
tivation at both the levels of gene transcription and/or
gene product translation (11,12), it is premature to con-
clude that the DNA replication phase of the cell cycle
phenotypeisnecessarilytheimportantpartininitiation.
Nature ofthe Initiated Cell
In any concern aboutmechanism, akey consideration
is the nature of the initiated target cell. It is clearly
evident that in no in vivo system studied does an ini-
tiated cell express anycapacity forautonomous cellpro-
liferation. Given the validity of this conclusion, what
then is the special phenotype of initiated cells that al-
lows them to participate in clonal expansion when the
appropriate promoting environment is created?
We have areasonable formulation inonlyone system,
the liver. In the rat, about 100 different chemical car-
cinogens induce in a rare hepatocyte a resistance phen-
otype during initiation (3,21,22,24-26). This phenotype
has a whole constellation of components (Table 4), in-
cluding large decreases in the cytochromes P-450, cy-
tochrome b5, and several mixed-function oxygenase
activities (phase I components), and considerable in-
creases in phase II components such as glutathione,
glutathione-S-transferases, UDP-glucuronyl transfer-
ase I, DT-diaphorase (quinone reductase), and a special
glutathione-S-transferase P (27,28). Included is a re-
Table 4. Biochemical pattern of hepatocyte nodules for
metabolizing xenobiotics.
Decrease in Increase in
Phase I Cytochrome P-450
Cytochrome b5
Several mixed-function
oxidases
Phase II Glutathione
Glutathione-S-
transferases
UDP-glucuronyl-
transferase I
y-Glutamyltransferase
Other Sulfotransferase Epoxide hydrolase
DT-diaphorase
Glutathione-S-transferase
P (P50)
sistance to the inhibitory effects ofseveral carcinogens
including 2-acetylaminofluorene on cell proliferation, a
resistance tothe cytotoxic effects ofthe senecioalkaloid
lasiocarpine and of polybrominated biphenyls (PBBs),
and a resistance to the induction of fatty change (tri-
glyceride accumulation) on feeding a choline deficient
diet (16).
This resistance enables at least some initiated hepa-
tocytes to respond to a promoting environment that
provides simultaneously a mitogenic stimulus and an
inhibition ofcell proliferation ofthe vast number ofun-
initiated hepatocytes. With such differential inhibition
(29), only the few resistant initiated hepatocytes can
respond to generate hepatocyte nodules very rapidly.
These focal collections of altered hepatocytes undergo
at least 10 to 12 cell cycles ofproliferation to generate
grossly visible nodules.
In the skin of mice, initiation is associated with the
acquisition ofresistance to terminal differentiation (30).
Whether the resistant cells are initiated and are the
precursors forpapillomas andultimately carcinomasre-
mains to be established.
Promotion
The promoting capability of carcinogens or of non-
initiating or poorly initiating promoting agents or pro-
moters is still poorly understood.
As already indicated above, the phenotype ofthe in-
itiated cell does not include any autonomous or spon-
taneous cell proliferation. Ifthe initiated cells are to be
expanded by cell proliferation (clonal expansion), they
somehow must be stimulated or encouraged to prolif-
-erate. This can be accomplished by at least three dif-
ferent mechanisms: differential inhibition, differential
stimulation, and differential recovery (29). In only one
case, the rat liver, do we know that differential inhi-
bition plays amajorrole in the mechanism ofpromotion
with carcinogens (3,21,22,24-26). Under these condi-
tions, theinitiated cellsrespondtoanordinarystimulus
forcell proliferation, astimulus forregeneration. Thus,
the carcinogen, by inhibiting the response ofthe unin-
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Table 5. Biological patterns of cancer development.
Site Type
With discrete focal Skin Papillomas
proliferations as Urinary bladder Papillomas
putative Liver Nodules
precancerous Colon Polyps
steps
Without obvious Cervix Atypical hyperplasia,
focal discrete Skin dysplasia,
proliferations Bronchi carcinoma in situ,
etc.
Without any e.g., acute
evident precursor transforming
or precancerous retroviral
lesions neoplasms (?)
itiated sensitive cells, the vast majority ofhepatocytes,
isabletoindirectlyselect fortheinitiated cells. Clearly,
no special receptors or altered receptors need be ac-
quired by the initiated cells, onlythe ordinary ones that
enable control hepatocytes to respond to many phys-
iological or pathological mitogenic stimuli.
Perhaps this same mechanism, differentialinhibition,
may also apply to the skin under some circumstances
(30), eventhoughthe nature ofthe stimulusisnotclear.
With phorbol esters as promoters, all the epidermal
responsive cells, initiated and uninitated, respond. If
the initiated ones show less terminal differentiation to
keratin-producing cells, they could become the basis for
papilloma formation by differential recovery (29).
These considerations apply to one group ofexamples
ofcancerdevelopment (Table 5), thoseinwhich discrete
focalproliferations occurregularly. Inthesecondgroup,
those associated with dysplasia and carcinoma in situ,
we have no current hypotheses for mechanisms. What
is seen is an obvious disturbance in differentiation, such
that the basal cells continue to proliferate and do not
show normal differentiation (terminal differentiation?).
The persistent papillomas, nodules, and polyps are sim-
ilar in one respect; they also show a disturbance in dif-
ferentiationtothematurephenotype. Whetherthissim-
ilarity between the patterns in groups I and II is basic
is not known, despite its attractiveness as a superficial
hypothesis.
With respect to the mechanism in group I, a key
question is whether clonal expansion is sufficient to al-
low a small population of nodules, papillomas, and po-
lyps to persist and undergo a long series ofsubsequent
steps leading to cancer (Fig. 1). The clarification ofthis
A. Amplification ofinitiated cells
("clonal expansion") ' Neoplasia
B. Amplification of Additional
initiated cells + alterations in gene - Neoplasia
expression
FIGURE 1. Hypotheses of promotion.
Table 6. Commonality in phenotype of preneoplastic and
precancerous hepatocyte nodules.
Architecture of hepatocyte
Blood supply of nodules
Ultrastructure and organization
Biochemical pattern of handling xenobiotics
Redifferentiation (remodeling) to adult liver.
basic question will probably have to await much further
insights into the many steps between the focal prolif-
erations and cancer, the steps called collectively pro-
gression.
Agents Versus Processes
It is already evident that any hope ofunderstanding
the action of any agent, be it exogenous (carcinogen,
promoter, etc.) orendogenous (aspecificgene orgenes),
seems remote. In respect to the product of initiation-
promotion, a focal proliferation, there appears to be
very little relation between special properties of the
agents and the tissue response. For example, in the
liver, the hepatocyte nodules and their precursors, the
foci or islands, are remarkably similar with a common
phenotype, regardless ofthe varied nature of different
carcinogens and promoters (16,17,27,28) (Table 6).
Thus, ifwe are to understand cancer development in
any depth, and if we are to develop rational ways to
prevent cancer by interrupting its development, we
shall have to begin to emphasize much more the study
of the fundamental cellular.nature of the various steps
between the nodule-papilloma-polyp and the ultimate
appearance of cancer.
In this context, it may be interesting to recall the
dynamic responsive nature of cells and how important
this is to our eventual understanding ofcarcinogenesis.
"The cell is the smallest integrating unit in biology: a
pseudo-intelligent computer that receives, screens,
changes, reacts toand adaptsto ahost ofenvironmental
signals. Much of this ability is apparently designed,
through evolution, for cell survival and host survival"
(31).
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